ArticleMolecular psychiatry2026
Meningeal macrophages alleviate social memory defects in an early Alzheimer's disease model.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Central nervous system lymphatic network: from the maintenance of brain homeostasis to emerging therapeutic perspectives in neurodegenerative diseases.Translational neurodegeneration · 2026Review
- Review
- Microglial handling of myelin debris and remyelination after ischaemic stroke: recognition, intracellular processing, lipid fate, and oligodendroglial repair.Frontiers in cellular neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Macrophages are enriched in the meninges, but their pathophysiological functions remain unclear. Here, we report the involvement of meningeal macrophages in the pathogenesis of Alzheimer's disease (AD). Specifically, M2-like macrophages with high levels of transforming growth factor-β1 (TGF-β1) were increased in the cerebrospinal fluid of patients with mild cognitive impairment and the meninges of young 5×FAD mice. Targeting meningeal macrophages to inhibit TGF-β1 exacerbated social behavioral defects, β-amyloid (Aβ) accumulation, and myelin damage in the medial prefrontal cortex (mPFC) of 5×FAD mice. Conversely, supplementation with M2-like macrophages or viral overexpression of TGF-β1 in meningeal macrophages ameliorated these effects. Mechanistically, meningeal macrophages facilitated the clearance of Aβ and secrete TGF-β1 to enhance oligodendrocyte maturation and microglial phagocytosis in the mPFC, thereby promoting myelin-dependent social memory. Collectively, the results of this study reveal that meningeal macrophages counteract early AD-like pathology and serve as a potential therapeutic target for treating neurodegenerative diseases.
Indexed as
Identifiers
41276614What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.